TMX Newsfile·2026-03-01 22:29Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Corcept Therapeutics Incorporated common stock during the specified Class Period, indicating potential legal issues surrounding the company's New Drug Application for relacorilant [1][5]. Group 1: Lawsuit Details - The class action lawsuit is focused on the period between October 31, 2024, and December 30, 2025, during which Corcept allegedly misrepresented the status of its NDA for relacorilant, claiming strong support from clinical trials while the FDA had raised concerns about the evidence [1][5]. - Investors are encouraged to join the class action without incurring out-of-pocket fees, as compensation may be available through a contingency fee arrangement [2]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant amounts for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including a notable $438 million secured for investors in 2019 [4]. Group 3: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the firm directly for more information [3][6]. - It is noted that no class has been certified yet, and investors have the option to select their counsel or remain absent from the class at this stage [7].